Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alyssa Dunn

Physician Assistant, Medical Derry, NH Physician Assistant

NPI 1790139244 CMS profile 10489385

6 Tsienneto Rd Ste 301, Derry, NH 03038

Open in the dashboard

General payments

$8,343

419 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alyssa Dunn of Derry, NH is reported in the CMS Open Payments database as having received $8,343 across 419 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,417 108
2024 General $2,203 109
2023 General $1,034 58
2022 General $1,697 81
2021 General $992 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alyssa Dunn
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Alyssa Dunn were reported at $2,417. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Alyssa Dunn Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $992 $156 $41–$563 $132
2022 $1,697 $185 $55–$649 $149
2023 $1,034 $199 $58–$717 $160
2024 $2,203 $206 $62–$740 $164
2025 $2,417 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,697 143 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,674 114 payments
  3. Janssen Biotech, Inc. $656 25 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $592 30 payments
  5. Gilead Sciences, Inc. $508 21 payments
  6. Genzyme Corporation $505 17 payments
  7. Celgene Corporation $494 18 payments
  8. Ironwood Pharmaceuticals, Inc $316 15 payments
  9. Regeneron Healthcare Solutions, Inc. $251 8 payments
  10. Pfizer Inc. $157 7 payments
  11. Other $493 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,145 415 payments
  2. Education $198 4 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,743 128 payments
  2. CREON $1,180 70 payments
  3. LINZESS $1,064 53 payments
  4. MAVYRET $672 32 payments
  5. ZEPOSIA $592 20 payments
  6. DUPIXENT $505 17 payments
  7. ENTYVIO $471 23 payments
  8. TRULANCE $438 23 payments
  9. STELARA $378 15 payments
  10. TREMFYA $365 14 payments
  11. Other $3,054 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

562

Median for Physician Assistant: 241

Drug cost

$93,324

Median for Physician Assistant: $4,110

Branded share of claims

14.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 23 $64,561
Linzess Linaclotide Brand 14 $18,702
Omeprazole Generic 165 $2,888
Pantoprazole Sodium Generic 175 $2,436
Sucralfate Generic 12 $1,769
Famotidine Generic 95 $1,222
Esomeprazole Magnesium Generic 21 $1,034
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 13 $248
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $227
Dicyclomine Hcl Generic 15 $166

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
$426 — —
MAVYRET
$219 — —
CREON
$205 23 —
DUPIXENT
$195 — —
LINZESS
$188 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

419 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record